GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (LSE:4BB) » Definitions » Asset Impairment Charge

4basebio (LSE:4BB) Asset Impairment Charge : £0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is 4basebio Asset Impairment Charge?

4basebio's Asset Impairment Charge for the six months ended in Jun. 2024 was £0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 was £0.00 Mil.


4basebio Asset Impairment Charge Historical Data

The historical data trend for 4basebio's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Asset Impairment Charge Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Impairment Charge
- - - - -

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

4basebio Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.


4basebio Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of 4basebio's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


4basebio Business Description

Traded in Other Exchanges
Address
25 Norman Way, Over, Cambridge, GBR, CB24 5QE
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio Headlines

No Headlines